MD Anderson Cancer Center

Cancer Treatment Centers of America names Maurie Markman president

Thursday, May 29, 2014 01:39 PM

Cancer Treatment Centers of America (CTCA), a national network of five hospitals that specialize in the treatment of patients fighting complex or advanced-stage cancer, has appointed Maurie Markman, M.D., president of the company's Medicine & Science unit, where he will be responsible for advancing the organization's overall commitment to clinical excellence, innovation, safety and patient satisfaction. Markman was senior vice president of Clinical Affairs and national director of Medical Oncology at CTCA.

More... »

WIRB Copernicus Group

Kapil Dhingra joins Advanced Accelerator Applications board of directors

Friday, May 2, 2014 11:13 AM

Advanced Accelerator Applications (AAA), an international specialist in molecular nuclear medicine, has announced that Dr. Kapil Dhingra has joined the company board of directors as an independent non-executive director.

More... »

CRF Health eCOA webinar series

MD Anderson, GSK form immunotherapy collaboration

Thursday, April 10, 2014 02:00 PM

The University of TexasMD Anderson Cancer Center has formed a research alliance with global pharmaceutical developer GlaxoSmithKline (GSK) to strengthen its efforts in advancing therapies that train the body's immune system to combat cancer.

More... »

WaveCheck receives $100,000 from Ontario Institute for Cancer Research

Wednesday, April 9, 2014 12:33 PM

WaveCheck has received a $100,000 catalyst grant from the Ontario Institute for Cancer Research (OICR). The funding builds upon MaRS Innovation's Indiegogo crowdfunding campaign for WaveCheck, which successfully raised over $50,000 from over 500 supporters worldwide over two months last fall.

More... »

MD Anderson, MedImmune collaborate on cancer immunotherapy

Monday, March 17, 2014 01:42 PM

The University of TexasMD Anderson Cancer Center and MedImmune, the global biologics R&D arm of AstraZeneca, will collaborate through MD Anderson's Moon Shots Program to develop therapies that unleash patients' immune systems to attack their cancers.

More... »

New presurgery combination therapy for triple-negative breast cancer

Tuesday, December 17, 2013 08:13 AM

The I-SPY 2 trial, an innovative, multidrug, phase II breast cancer trial, has yielded positive results with the first drug to complete testing in the trial. Adding the chemotherapy carboplatin and the molecularly targeted drug veliparib to standard presurgery chemotherapy improved outcomes for women with triple-negative breast cancer.

More... »

Bayer HealthCare, University of Texas MD Anderson Cancer Center collaborate

Monday, December 16, 2013 02:28 PM

Bayer HealthCare has signed a master agreement for the performance of clinical trials with Houston-based University of TexasMD Anderson Cancer Center.

More... »

GSK launches global consortium with six cancer research centers

Friday, December 6, 2013 12:54 PM

GlaxoSmithKline has formed the Oncology Clinical and Translational Consortium (OCTC), a collaborative scientific research network comprised of six international cancer centers. The centers include Gustave Roussy (Villejuif, France), University of TexasMD Anderson Cancer Center (Houston), Memorial Sloan-Kettering Cancer Center (New York), Netherlands Cancer Institute, Princess Margaret Cancer Center, University Health Network (Toronto, Canada) and Vall d’Hebron Institute of Oncology-VHIO (Barcelona, Spain). 

More... »

MD Anderson selects Oracle applications and tech to help transform cancer care

Friday, February 1, 2013 11:26 AM

The University of Texas MD Anderson Cancer Center, a center devoted exclusively to cancer patient care, research, education and prevention, has selected Oracle Health Sciences applications and Oracle technology as the foundation for an organization-wide analytics initiative designed to enable a new generation of personalized cancer treatment that improves outcomes. 

More... »

UT MD Anderson, GSK collaborate on new approach to cancer immune therapy

Friday, December 7, 2012 02:06 PM

The University of Texas MD Anderson Cancer Center and global healthcare company GlaxoSmithKline (GSK) have signed a research collaboration and license agreement to develop new therapeutic antibodies that promote an immune system attack against cancer.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 21

As job growth in drug development sector soars, more employees are seeking new opportunities

U.K. study: Prisoners should have the right to participatein clinical trials on moral grounds, for healthcare access

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs